New Drug Approvals

Home » Uncategorized » A Flow Reactor with Inline Analytics: Design and Implementation

A Flow Reactor with Inline Analytics: Design and Implementation

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Archives

Categories

Recent Posts

Blog Stats

  • 4,802,109 hits

Unknown's avatar

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers

add to any

Share

Figure

A Flow Reactor with Inline Analytics: Design and Implementation

Org. Process Res. Dev., 2014, 18 (11), pp 1315–1320
DOI: 10.1021/op5002512
Kristina Somerville, Michael Tilley, Guanlong Li, Debasis Mallik, and Michael G. Organ
pp 1315–1320
Publication Date (Web): October 13, 2014 (Article)
DOI: 10.1021/op5002512
http://pubs.acs.org/doi/full/10.1021/op5002512
A continuous flow system complete with inline analytics is described. Sampling from a high pressure reactor and automated delivery mechanisms are detailed. The ability of the system to maintain critical process parameters (CPP) throughout a reaction process is demonstrated. Setup performance was evaluated using the Claisen rearrangement of allyl phenyl ether (1).
Flow synthesis has garnered industrial interest from the promise of reducing wasteful and inefficient batch-manufacturing process development(1) by replacing the conventional “scale up” approach with “scale out” continuous production.(2) The development of synthetic protocols to supply material for early phase discovery (medicinal chemistry), formulation, and clinical trials consumes significant time and resources and carries a high cost.(3) Further, the effort put into developing a robust and compliant batch scale-up methodology goes for naught if the active pharmaceutical ingredient (API) ultimately fails later stage trials. By developing a flow process early on, any amount of product required may be obtained by running the flow system with the same conditions for the appropriate length of time. The promise of flow technology is that, once optimized, a process remains viable through the entire drug development process. Furthermore, quality by design (QbD) can be facilitated by flow synthesis because of the ability to closely monitor and control CPPs (those parameters “whose variability has an impact on a critical quality attribute (CQA) and therefore should be monitored or controlled to ensure the process produces the desired quality,” e.g., temperature, flow rate, stoichiometry; “where a CQA is a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality,”(4) e.g., yield, impurity) during a run.(5) Ultimately, flow-reactor technology will be employed for full-scale commercial API production.(6)

  • 1.

    Wu, H., Dong, Z., Haitao, L., and Khan, M. Org. Process Res. Dev. 2014, 18, 10.1021/op500056a.

  • 2.

    (a) Razzaq, T.; Kappe, C. O. Chem.—Asian J. 2010, 5, 1274– 1289

    (b) Wiles, C.; Watts, P. Green Chem. 2014, 16, 55– 62

    (c) Moseley, J. D.; Woodman, E. K. Org. Process Res. Dev. 2008, 12, 967– 981

  • 3.

    Ullah, F.; Samarakoon, T.; Rolfe, A.; Kurtz, R. D.; Hanson, P. R.; Organ, M. G. Chem.—Eur. J. 2010, 16, 10959– 10962

    and references cited therein

  • 4.

    Guidance for Industry, Q8(R2) Pharmaceutical Development; U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Silver Springs, MD, 2009; p 18.

  • 5.

    Calibrese, G. S.; Pissavini, S. AIChE J. 2011, 54, 828– 834

  • 6.

    (a) Alsten, J. G.; Reeder, L. M.; Stanchina, C. L.; Knoechel, D. J. Org. Process Res. Dev. 2008, 12, 989– 994

    (b) Roberge, D. M.; Zimmermann, B.; Rainonee, F.; Gottsponer, M.; Eyholzer, M.; Kockmann, N. Org. Process Res. Dev. 2008, 12, 905– 910

 DEDICATED TO A PIONEER IN THIS FIELD
Vijay Kirpalani

Vijay Kirpalani

vk@pi-inc.co

CEO

Pi-inc (Process Intensification Experts LLP)

READ AT….https://newdrugapprovals.org/2014/11/11/flow-chemistry-test-facility-in-india/

Toronto, canada

Tags: ,

By in Uncategorized on .

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

View Full Profile →

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.